-
Something wrong with this record ?
Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy
S. Vesely, L. Jarolim, M. Schmidt, J. Do Carmo Silva, K. Duskova, M. Babjuk,
Language English Country England, Great Britain
Document type Journal Article
Grant support
NV15-33910A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Medline Complete (EBSCOhost)
from 2013-02-01
- MeSH
- Radiotherapy, Adjuvant MeSH
- Time Factors MeSH
- Risk Assessment methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local blood MeSH
- Prostatic Neoplasms blood radiotherapy surgery MeSH
- Area Under Curve MeSH
- Postoperative Period MeSH
- Disease-Free Survival MeSH
- Unnecessary Procedures statistics & numerical data MeSH
- Prostatectomy MeSH
- Prostate-Specific Antigen blood MeSH
- ROC Curve MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: The aim of this study was to construct a stratification model based on early postoperative kinetics of prostate-specific antigen (PSA) to select the most suitable high-risk patients for early intervention after radical prostatectomy (RP). MATERIALS AND METHODS: The study evaluated 205 men who had undergone RP without any adjuvant treatment. All of the patients had positive surgical margins, extracapsular extension and/or seminal vesicle invasion. The patients underwent multiple ultrasensitive PSA measurements on days 14, 30, 60 and 90 after RP, and subsequently at 3 month intervals. The ability of particular PSA measurements to predict biochemical recurrence (BCR) was assessed using the area under the curve (AUC). A sequential mathematical decision procedure was constructed to create a stratification model. RESULTS: During the median follow-up of 45.9 months, 106 patients (51%) experienced BCR. Prediction of BCR in terms of the AUC for PSA measurements on days 14, 30, 60 and 90 after the surgery was 0.61, 0.70, 0.80 and 0.82, respectively. In the multivariate analysis, only PSA after RP remained as a predictor of progression-free survival (p < 0.001). The stratification model based on calculated cut-off values for PSA on day 30 (0.068 ng/ml) and PSA on day 60 (0.015 ng/ml) reduced the potential overtreatment rate by 37%. CONCLUSIONS: The results imply that ultrasensitive PSA values obtained very early after RP correlate with the presence of recurrent disease in high-risk patients. Incorporating these readily available variables into risk stratification models may help to individualize the administration of adjuvant radiotherapy and thus to minimize overtreatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024915
- 003
- CZ-PrNML
- 005
- 20201116083702.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/21681805.2017.1292545 $2 doi
- 035 __
- $a (PubMed)28635569
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vesely, Stepan $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 245 10
- $a Stratification model based on early postprostatectomy prostate-specific antigen kinetics may help to reduce the risk of overtreatment in candidates for adjuvant radiotherapy / $c S. Vesely, L. Jarolim, M. Schmidt, J. Do Carmo Silva, K. Duskova, M. Babjuk,
- 520 9_
- $a OBJECTIVE: The aim of this study was to construct a stratification model based on early postoperative kinetics of prostate-specific antigen (PSA) to select the most suitable high-risk patients for early intervention after radical prostatectomy (RP). MATERIALS AND METHODS: The study evaluated 205 men who had undergone RP without any adjuvant treatment. All of the patients had positive surgical margins, extracapsular extension and/or seminal vesicle invasion. The patients underwent multiple ultrasensitive PSA measurements on days 14, 30, 60 and 90 after RP, and subsequently at 3 month intervals. The ability of particular PSA measurements to predict biochemical recurrence (BCR) was assessed using the area under the curve (AUC). A sequential mathematical decision procedure was constructed to create a stratification model. RESULTS: During the median follow-up of 45.9 months, 106 patients (51%) experienced BCR. Prediction of BCR in terms of the AUC for PSA measurements on days 14, 30, 60 and 90 after the surgery was 0.61, 0.70, 0.80 and 0.82, respectively. In the multivariate analysis, only PSA after RP remained as a predictor of progression-free survival (p < 0.001). The stratification model based on calculated cut-off values for PSA on day 30 (0.068 ng/ml) and PSA on day 60 (0.015 ng/ml) reduced the potential overtreatment rate by 37%. CONCLUSIONS: The results imply that ultrasensitive PSA values obtained very early after RP correlate with the presence of recurrent disease in high-risk patients. Incorporating these readily available variables into risk stratification models may help to individualize the administration of adjuvant radiotherapy and thus to minimize overtreatment.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x krev $7 D009364
- 650 _2
- $a pooperační období $7 D011184
- 650 _2
- $a prostatický specifický antigen $x krev $7 D017430
- 650 _2
- $a prostatektomie $7 D011468
- 650 _2
- $a nádory prostaty $x krev $x radioterapie $x chirurgie $7 D011471
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a adjuvantní radioterapie $7 D018714
- 650 _2
- $a hodnocení rizik $x metody $7 D018570
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a procedury zbytečné $x statistika a číselné údaje $7 D019564
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jarolim, Ladislav $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 700 1_
- $a Schmidt, Marek $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 700 1_
- $a Do Carmo Silva, Joana $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 700 1_
- $a Duskova, Katerina $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 700 1_
- $a Babjuk, Marko $u a Department of Urology , Charles University 2nd Medical Faculty and University Hospital Motol , Prague , Czech Republic.
- 773 0_
- $w MED00193240 $t Scandinavian journal of urology $x 2168-1813 $g Roč. 51, č. 2 (2017), s. 114-119
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28635569 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20201116083701 $b ABA008
- 999 __
- $a ok $b bmc $g 1317046 $s 1021836
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 51 $c 2 $d 114-119 $e 20170224 $i 2168-1813 $m Scandinavian journal of urology $n Scand J Urol $x MED00193240
- GRA __
- $a NV15-33910A $p MZ0
- LZP __
- $a Pubmed-20180709